Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC
Jessica A. Hellyer, Jacqueline V. Aredo, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee
Topics & Concepts
MedicineDurvalumabOncologyInternal medicineRegimenCohortRetrospective cohort studyCancerImmunotherapyNivolumabLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas